Журнал "Нирки" том 11, №1

Çì³ñò / Contents
Çì³ñò
Ñòîð³íêà ðåäàêòîðà
Çâåðíåííÿ ãîëîâíîãî ðåäàêòîðà ............................... 5
Îðèã³íàëüí³ ñòàòò³
Fateme Shamekhi
Âïëèâ ìóòàö³¿ FN1 íà ðåçóëüòàòè
ô³áðîíåêòèíîâî¿ ãëîìåðóëîïàò³¿:
ñèñòåìíèé îãëÿä òà ìåòààíàë³ç ............................. 6
×óá Î.²., Òåñëåíêî Ñ.Â., ×óá Î.Â.
Âèÿâëåííÿ ïëàçì³äíèõ ãåí³â
àíòèá³îòèêîðåçèñòåíòíîñò³ ESBLs
òà PMQR ñåðåä óðîïàòîãåí³â,
âèä³ëåíèõ â³ä ïàö³ºíò³â ç äîä³àë³çíîþ ÕÕÍ
òà ﳺëîíåôðèòîì ................................................... 14
Íàñòàíîâè
Íàñòàíîâè KDIGO 2021 äëÿ êë³í³÷íî¿ ïðàêòèêè
ç óïðàâë³ííÿ ãëîìåðóëÿðíèìè õâîðîáàìè ........ 23
Êë³í³÷í³ ïðàêòè÷í³ ðåêîìåíäàö³¿ Áðèòàíñüêî¿
íèðêîâî¿ àñîö³àö³¿: ³íã³áóâàííÿ íàòð³éçàëåæíîãî
êîòðàíñïîðòåðà ãëþêîçè 2-ãî òèïó (ÍÇÊÒÃ-2)
ó äîðîñëèõ ³ç õâîðîáîþ íèðîê ............................ 34
Îíîâëåííÿ ùîäî çàñòîñóâàííÿ òîëâàïòàíó
äëÿ ë³êóâàííÿ àâòîñîìíî-äîì³íàíòíîãî
ïîë³ê³ñòîçó íèðîê (ÀÄÏÍ): êîíñåíñóñíà
çàÿâà â³ä ³ìåí³ Ðîáî÷î¿ ãðóïè ERA ç³ ñïàäêîâèõ
çàõâîðþâàíü íèðîê, ªâðîïåéñüêî¿ äîâ³äêîâî¿
ìåðåæ³ ç ð³äê³ñíèõ çàõâîðþâàíü íèðîê
òà Polycystic Kidney Disease International ........... 41
Ïîãëÿä íà ïðîáëåìó
²âàíîâ Ä.Ä.
Íèðêîâîçàì³ñíà òåðàï³ÿ òà ãëîáàëüí³ ïðîáëåìè:
ñâ³òîâèé äîñâ³ä òà íàø³ âèêëèêè ........................... 44
Êë³í³÷íå ñïîñòåðåæåííÿ
×óá Î.²., Äÿäèê Î.Î., ²âàíîâ Ä.Ä.
Ìåçàíã³îïðîë³ôåðàòèâíèé ãëîìåðóëîíåôðèò
³ç äåïîçèòàìè ìîíîêëîíàëüíèõ ³ìóíîãëîáóë³í³â:
÷îìó íåôðîá³îïñ³ÿ ìຠâèð³øàëüíå çíà÷åííÿ ....49
Îãëÿä
Äåíîâà Ë.Ä., ²âàíîâ Ä.Ä.
Âïëèâ îêñèäàíòíîãî, êàðáîí³ëüíîãî
òà í³òðîçàòèâíîãî ñòðåñ³â íà ïåðåá³ã õðîí³÷íî¿
õâîðîáè íèðîê (àíàë³òè÷íèé îãëÿä) .................... 57
Îô³ö³éíà ³íôîðìàö³ÿ
Âñåñâ³òí³é äåíü íèðêè — 2022 â Óêðà¿í³ .................... 66
Âñåñâ³òí³é äåíü íèðêè — 2022 â Óêðà¿í³.
Çäîðîâ’ÿ íèðîê äëÿ âñ³õ ........................................ 71
Äëÿ íàøèõ ïàö³ºíò³â
ijàãíîñòèêà çàõâîðþâàíü íèðîê .............................. 75
Contents
Editor’s Page
Appeal of Editor-in-Chief ............................................... 5
Original Articles
Fateme Shamekhi
Effect of FN1 mutation on outcomes
of fibronectin glomerulopathy in a systematic
review and meta-analysis ......................................... 6
O.². Chub, S.V. Teslenko, O.V. Chub
Expression of plasmid-mediated
resistance genes ESBLs
and PMQR among uropathogens,
isolated from non-dialysis CKD
patients with pyelonephritis .................................... 14
Guidelines
KDIGO 2021 Clinical Practice Guideline
for the Management of Glomerular Diseases ...... 23
UK Kidney Association Clinical
Practice Guideline: Sodium-Glucose
Co-transporter-2 (SGLT-2)
Inhibition in Adults with Kidney Disease ................. 34
An update on the use of tolvaptan for autosomal
dominant polycystic kidney disease:
consensus statement on behalf
of the ERA Working Group on Inherited
Kidney Disorders, the European Rare Kidney
Disease Reference Network and Polycystic
Kidney Disease International ................................. 41
Looking at the Ðroblem
D.D. Ivanov
Kidney replacement therapy and global issues:
world experience and our challenges .................. 44
Clinical Observation
O.I. Chub, O.O. Dyadyk, D.D. Ivanov
Mesangial proliferative glomerulonephritis
with monoclonal immunoglobulin deposits:
why nephrobiopsy is crucial ................................... 49
Review
L.D. Denova, D.D. Ivanov
Influence of oxidative, carbonyl,
and nitrosative stresses on the course
of chronic kidney disease (analytical review) ...... 57
Official Information
World Kidney Day 2022 in Ukraine ............................... 66
World Kidney Day 2022 in Ukraine.
Kidney health for everyone .................................... 71
For Our Patients
Diagnosis of kidney disease ......................................... 75
4 Íèðêè, ISSN 2307-1257 (print), ISSN 2307-1265 (online) Òîì 11, ¹ 1, 2022